These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 21696807

  • 1. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
    Zhang K, Yu W, Jin J, Ye H, Wang X, Zhang N, Yang Y, Zhong C, Wan B.
    Urology; 2011 Sep; 78(3):636-40. PubMed ID: 21696807
    [Abstract] [Full Text] [Related]

  • 2. Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
    Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH.
    Int J Clin Pract; 2011 Nov; 65(11):1193-9. PubMed ID: 21995695
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T.
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 5. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z, Zhang Y, Ding Q, He Z, Wang J, Xu K.
    Int J Urol; 2007 Feb 27; 14(2):118-22. PubMed ID: 17302567
    [Abstract] [Full Text] [Related]

  • 8. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.
    Pompeo AC, Rosenblatt C, Bertero E, DA Ros CT, Cairoli CE, Damião R, Wroclawski ER, Koff WJ, Mesquita F, Pinheiro GE, Doxazosin and Tamsulosin Study Investigator Group.
    Int J Clin Pract; 2006 Oct 27; 60(10):1172-7. PubMed ID: 16942589
    [Abstract] [Full Text] [Related]

  • 9. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov 27; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 10. [Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS].
    Huang SY, Zhu SX, Zeng BW, Zhu DS, Fang RJ.
    Zhonghua Nan Ke Xue; 2010 Sep 27; 16(9):807-10. PubMed ID: 21171265
    [Abstract] [Full Text] [Related]

  • 11. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E, European Silodosin Study Group.
    Eur Urol; 2011 Mar 27; 59(3):342-52. PubMed ID: 21109344
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS.
    BJU Int; 2003 Jan 27; 91(1):41-4. PubMed ID: 12614248
    [Abstract] [Full Text] [Related]

  • 14. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.
    Urology; 2008 Nov 27; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
    Sun GH, Tsui KH, Wu TT, Chang CH, Cheng CL, Schou M.
    Kaohsiung J Med Sci; 2010 Oct 27; 26(10):532-9. PubMed ID: 20950778
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of naftopidil on nocturia after failure of tamsulosin.
    Oh-oka H.
    Urology; 2008 Nov 27; 72(5):1051-5. PubMed ID: 18817955
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
    Cao Y, Wang Y, Guo L, Yang X, Chen T, Niu H.
    Med Sci Monit; 2016 Jun 04; 22():1895-902. PubMed ID: 27260129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.